Abbott Laboratories (ABT) Competitors $133.78 +0.04 (+0.03%) As of 12:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABT vs. DXCM, ISRG, TSLA, ABBV, BSX, ELV, ITGR, JNJ, MDT, and TMOShould you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include DexCom (DXCM), Intuitive Surgical (ISRG), Tesla (TSLA), AbbVie (ABBV), Boston Scientific (BSX), Elevance Health (ELV), Integer (ITGR), Johnson & Johnson (JNJ), Medtronic (MDT), and Thermo Fisher Scientific (TMO). Abbott Laboratories vs. Its Competitors DexCom Intuitive Surgical Tesla AbbVie Boston Scientific Elevance Health Integer Johnson & Johnson Medtronic Thermo Fisher Scientific Abbott Laboratories (NYSE:ABT) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Do insiders & institutionals believe in ABT or DXCM? 75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ABT or DXCM more profitable? Abbott Laboratories has a net margin of 32.43% compared to DexCom's net margin of 13.29%. DexCom's return on equity of 30.41% beat Abbott Laboratories' return on equity.Company Net Margins Return on Equity Return on Assets Abbott Laboratories32.43% 18.32% 10.71% DexCom 13.29%30.41%10.08% Which has stronger valuation & earnings, ABT or DXCM? Abbott Laboratories has higher revenue and earnings than DexCom. Abbott Laboratories is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbbott Laboratories$41.95B5.55$13.40B$7.9816.76DexCom$4.03B6.47$576.20M$1.4446.18 Do analysts recommend ABT or DXCM? Abbott Laboratories currently has a consensus target price of $145.39, indicating a potential upside of 8.68%. DexCom has a consensus target price of $98.32, indicating a potential upside of 47.83%. Given DexCom's higher possible upside, analysts clearly believe DexCom is more favorable than Abbott Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abbott Laboratories 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 2 Strong Buy rating(s) 2.91DexCom 0 Sell rating(s) 6 Hold rating(s) 14 Buy rating(s) 3 Strong Buy rating(s) 2.87 Which has more volatility & risk, ABT or DXCM? Abbott Laboratories has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Does the media favor ABT or DXCM? In the previous week, Abbott Laboratories had 32 more articles in the media than DexCom. MarketBeat recorded 51 mentions for Abbott Laboratories and 19 mentions for DexCom. Abbott Laboratories' average media sentiment score of 1.50 beat DexCom's score of 0.72 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 46 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DexCom 9 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAbbott Laboratories beats DexCom on 10 of the 17 factors compared between the two stocks. Get Abbott Laboratories News Delivered to You Automatically Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABT vs. The Competition Export to ExcelMetricAbbott LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$232.98B$10.71B$6.13B$21.92BDividend Yield1.75%1.86%5.51%3.56%P/E Ratio16.7722.2285.5229.61Price / Sales5.5527.52585.1099.18Price / Cash20.4425.6126.3018.33Price / Book4.843.4613.164.60Net Income$13.40B$210.63M$3.30B$1.01B7 Day Performance-0.14%1.82%4.71%0.11%1 Month Performance0.65%1.40%8.36%2.22%1 Year Performance18.02%-5.70%87.42%13.68% Abbott Laboratories Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABTAbbott Laboratories4.96 of 5 stars$133.78+0.0%$145.39+8.7%+18.6%$232.98B$41.95B16.77114,000Positive NewsDXCMDexCom4.9614 of 5 stars$68.39+0.1%$99.11+44.9%-2.6%$26.81B$4.03B47.4710,300ISRGIntuitive Surgical4.9557 of 5 stars$442.91+1.1%$595.95+34.6%-6.7%$158.45B$8.35B61.6515,638Positive NewsAnalyst UpgradeTSLATesla4.1481 of 5 stars$427.88+1.1%$332.33-22.3%+81.2%$1.42T$97.69B247.05125,665Trending NewsAnalyst ForecastABBVAbbVie4.6268 of 5 stars$218.430.0%$223.45+2.3%+18.5%$386.56B$56.33B104.2055,000Trending NewsBSXBoston Scientific4.9299 of 5 stars$98.70+0.6%$118.17+19.7%+14.4%$146.08B$16.75B58.6853,000Analyst ForecastELVElevance Health4.6556 of 5 stars$317.18+0.2%$411.06+29.6%-28.9%$71.51B$177.01B13.51104,200Positive NewsAnalyst ForecastITGRInteger4.1035 of 5 stars$101.66-0.1%$140.25+38.0%-18.4%$3.56B$1.72B44.7611,000Positive NewsJNJJohnson & Johnson4.7384 of 5 stars$179.53+1.0%$181.40+1.0%+17.4%$432.33B$88.82B19.20138,100Trending NewsUpcoming EarningsAnalyst ForecastGap DownMDTMedtronic4.8286 of 5 stars$94.39+0.9%$102.27+8.3%+11.6%$120.96B$33.54B25.9895,000Positive NewsAnalyst ForecastTMOThermo Fisher Scientific4.8656 of 5 stars$461.97+0.6%$588.35+27.4%-9.0%$174.52B$42.88B26.73125,000Positive NewsAnalyst Upgrade Related Companies and Tools Related Companies DXCM Alternatives ISRG Alternatives TSLA Alternatives ABBV Alternatives BSX Alternatives ELV Alternatives ITGR Alternatives JNJ Alternatives MDT Alternatives TMO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABT) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abbott Laboratories Please log in to your account or sign up in order to add this asset to your watchlist. Share Abbott Laboratories With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
